Eli Lilly & Co. (NYSE: LLY) has experienced a remarkable over 635% increase in stock price between late 2020 and summer 2024, marking a transformative era for the pharmaceutical giant. This growth is attributed to innovative medicines, regulatory victories, and robust investments in both pipeline and manufacturing. However, the company reported a revenue shortfall in Q4 2023. As investors speculate on future movements, especially in light of acquisitions and potential regulatory impacts, analysts from 24/7 Wall St. provide forecasts regarding Lilly's stock trajectory from 2025 to 2030 based on projected financial performance.
Eli Lilly & Co. has seen over 635% stock growth since late 2020, driven by innovative medicines and regulatory successes but faced a revenue shortfall in Q4.
The question for investors is whether Eli Lilly's recent stock volatility is a pause or the beginning of another upward run, with projected revenue growth.
Lilly's stock saw a 4.7% increase since the start of the year due to recent acquisition news, amidst uncertainties over drug pricing reforms.
Experts at 24/7 Wall St. offer insights into Lilly's potential trajectory, focusing on future revenue and net income to estimate stock prices up to 2030.
Collection
[
|
...
]